Researchers from the Quantitative Biosciences Institute (QBI) Covid-19 Research Group (QCRG) at the University of California, San Francisco (UCSF) and their collaborators have identified 69 potential Covid-19 drug candidates and experimental compounds by studying the genes of Covid-19 to determine its mechanism of infection of human cells.
Of these candidates, 24 are already FDA approved to treat other indications. Repurposing these drugs could mean seeing faster results than by waiting on novel drug discovery.
Go deeper with GlobalData
The method of novel drug identification involved a systematic chemoinformatic drug search combined with a pathway-centric analysis. The researchers examined 26 of the 29 genes that Covid-19 uses to produce viral proteins. From this, they identified 332 human protein targets. Some of the viral proteins target a single human protein, whereas others target up to 12 proteins. Researchers then identified 69 drugs that interact with the human proteins targeted by Covid-19 for viral replication in human cells.
These drugs include the following: the CK2 inhibitor anticancer drug silmitasertib, the HDAC2 inhibitor apicidin, the ATPase inhibitor bafilomycin A11, the Sigma 1/2 modulator haloperidol, the Parkinson’s disease COMT inhibitor entacapone, the diabetes MRC1 inhibitor metformin, the viral infection IMPDH inhibitor ribavirin, the hypertension calcium ion channel inhibitor and drug efflux transporter inhibitor verapamil, the organ rejection mammalian target of rapamycin inhibitor rapamycin, the malaria treatment sigma-1 binder chloroquine, and the hypertension angiotensin-converting enzyme inhibitors captopril and lisinopril. Notably, these drug candidates have not yet been investigated for Covid-19, and some have yet to enter the pipeline.
Researchers have already started testing some of these compounds against laboratory-grown Covid-19 virus. GlobalData expects that the testing and identification of other drug candidates that can be repurposed for Covid-19 will continue as the situation unfolds, potentially resulting in a faster approved treatment for Covid-19.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
